Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Chronic Inflammatory Demyelinating Polyradiculoneuropathy, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Completed PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Tanabe Pharma Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Aomori, Japan , Athens, Greece , Auchenflower, Australia , Barcelona, Spain , Bochum, Germany , Boston, United States , Brussels, Belgium , Bunkyo, Japan , Burlington, United States and 56 more locations